Melbourne-based healthtech startup Everlab has raised AU$15 million (US$9.7 million) in a seed funding round led by Left Lane Capital, a global growth equity firm.

The funds will be used to expand its clinical and engineering teams, enhance its AI-powered platform, and support international growth through 2026.

Everlab offers a subscription-based platform for preventive care, providing diagnostics, AI reports, and doctor consultations.

The startup has integrated its platform with national pathology and radiology systems to ensure interoperability and compliance with regulations.

Everlab said its AI cuts review time from 10 hours to under 10 minutes, with results verified by licensed doctors.

Everlab claims over one million biomarkers analyzed, with early risk detection in 2.5% of users and growing demand across Australia.